ARTICLE | Company News
Matrix submits IntraDose MAA
November 26, 2001 8:00 AM UTC
MATX said it submitted an MAA to the EMEA for IntraDose cisplatin/epinephrine injectable gel to treat recurrent or refractory head and neck cancer. MATX also said the MAA was accepted for filing. Earl...